Synthetic lethal interaction of combined CD26 and Bcl‐xL inhibition is a powerful anticancer therapy against hepatocellular carcinoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1872-034x|45|9|1023-1033

ISSN： 1386-6346

Source： HEPATOLOGY RESEARCH, Vol.45, Iss.9, 2015-09, pp. : 1023-1033

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells

By Lee Su-Jin   Park Ho-Jin   Kim Young-Hwa   Kim Bo-Young   Jin Hyun-Seok   Kim Hyon J.   Han Jae-Ho   Yim Hyunee   Jeong Seon-Yong  

International Journal of Molecular Medicine, Vol. 30, Iss. 2, 2012-08 ,pp. : 443-450

Spandidos Publications

Access to resources Recommend Favorite

Bcl-2, Bax, Bcl-xL and Bcl-xS Expression in Neoplastic and Normal Endometrium

By  

Oncology, Vol. 58, Iss. 2, 2000-02 ,pp. : 161-168

Karger

Access to resources Recommend Favorite

Contrôle de l’expression de Bcl-xL par les facteurs de transcription Ets

By Zaldumbide Arnaud   Sevilla Lidia   Pognonec Philippe   Boulukos Kim E.  

Médecine/sciences, Vol. 17, Iss. 12, 2010-10 ,pp. : 1356-1357

Edp Sciences

Access to resources Recommend Favorite

Anticancer efficacy of a novel propofol–linoleic acid-loaded escheriosomal formulation against murine hepatocellular carcinoma

By Khan Azmat Ali   Jabeen Mumtaz   Khan Aijaz Ahmed   Owais Mohammad  

Nanomedicine, Vol. 20, Iss. 20, 2013-01 ,pp. : 1-14

Future Medicine

Access to resources Recommend Favorite

Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma

By  

CANCER, Vol. 121, Iss. 17, 2015-09 ,pp. : 2917-2925

John Wiley & Sons Inc

Access to resources Recommend Favorite